XTRA:CNWK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. More Details


Snowflake Analysis

Adequate balance sheet and fair value.

Share Price & News

How has co.don's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CNWK's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.5%

CNWK

-7.6%

DE Biotechs

-1.9%

DE Market


1 Year Return

-60.7%

CNWK

-5.4%

DE Biotechs

0.2%

DE Market

Return vs Industry: CNWK underperformed the German Biotechs industry which returned -5.4% over the past year.

Return vs Market: CNWK underperformed the German Market which returned 0.1% over the past year.


Shareholder returns

CNWKIndustryMarket
7 Day-3.5%-7.6%-1.9%
30 Day-14.2%-11.3%0.8%
90 Day-30.1%-12.2%-0.5%
1 Year-59.6%-60.7%-5.3%-5.4%3.4%0.2%
3 Year-88.8%-89.4%-0.2%-1.1%-0.2%-9.0%
5 Year-53.7%-60.3%39.7%37.5%21.4%4.0%

Price Volatility Vs. Market

How volatile is co.don's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is co.don undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CNWK (€0.88) is trading below our estimate of fair value (€2.57)

Significantly Below Fair Value: CNWK is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CNWK is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: CNWK is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CNWK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CNWK is good value based on its PB Ratio (1.8x) compared to the DE Biotechs industry average (3.9x).


Next Steps

Future Growth

How is co.don forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

87.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CNWK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CNWK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CNWK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CNWK's revenue (34.2% per year) is forecast to grow faster than the German market (6% per year).

High Growth Revenue: CNWK's revenue (34.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CNWK is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has co.don performed over the past 5 years?

-34.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CNWK is currently unprofitable.

Growing Profit Margin: CNWK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CNWK is unprofitable, and losses have increased over the past 5 years at a rate of 34.8% per year.

Accelerating Growth: Unable to compare CNWK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CNWK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).


Return on Equity

High ROE: CNWK has a negative Return on Equity (-85.21%), as it is currently unprofitable.


Next Steps

Financial Health

How is co.don's financial position?


Financial Position Analysis

Short Term Liabilities: CNWK's short term assets (€8.1M) exceed its short term liabilities (€4.7M).

Long Term Liabilities: CNWK's short term assets (€8.1M) exceed its long term liabilities (€3.3M).


Debt to Equity History and Analysis

Debt Level: CNWK is debt free.

Reducing Debt: CNWK had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CNWK has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CNWK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is co.don current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CNWK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CNWK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CNWK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CNWK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CNWK's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.1yrs

Average board tenure


CEO

Tilmann Bur (55 yo)

no data

Tenure

Mr. Tilmann Bur has been an Additional Member of the Executive Board of co.don AG since June 1, 2019 and served as its Chief Operating Officer until January 2020. Mr. Bur is an internationally experienced ...


Board Members

NamePositionTenureCompensationOwnership
Thomas Krause
Independent Member of the Supervisory Board8.08yrsno datano data
Hans-Joerg Bullinger
Member of Supervisory Board1.33yrsno datano data
Thommy Stählin
Independent Member of the Supervisory Board14.92yrsno datano data
Hans Bauerfeind
Independent Chairman of Supervisory Board2.83yrsno datano data
Beatrix Bauerfeind-Johnson
Independent Member of Supervisory Board4.17yrsno datano data
Barbara Sickmüller
Independent Member of the Supervisory Board10.25yrsno datano data

6.1yrs

Average Tenure

Experienced Board: CNWK's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 73.9%.


Top Shareholders

Company Information

co.don AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: co.don AG
  • Ticker: CNWK
  • Exchange: XTRA
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €33.435m
  • Shares outstanding: 37.82m
  • Website: https://www.codon.de

Number of Employees


Location

  • co.don AG
  • Warthestrasse 21
  • Teltow
  • Brandenburg
  • 14513
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNWKDB (Deutsche Boerse AG)YesCommon SharesDEEURFeb 2001
CNWKXTRA (XETRA Trading Platform)YesCommon SharesDEEURFeb 2001
0Q37LSE (London Stock Exchange)YesCommon SharesGBEURFeb 2001
CNWKdBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURFeb 2001

Biography

co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The company develops, produces, and markets autologous cell therapies for the ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/24 20:38
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.